Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.48% | -9.56% | 7.74% | 6.23% | -17.69% |
| Total Depreciation and Amortization | 12.06% | 19.00% | 24.68% | 44.81% | 64.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.44% | 58.18% | 7.32% | 59.27% | 108.64% |
| Change in Net Operating Assets | -28.29% | -104.28% | 292.73% | -22.08% | -168.22% |
| Cash from Operations | -0.41% | -235.34% | 28.78% | 12.25% | -23.68% |
| Capital Expenditure | 36.52% | 11.78% | 63.19% | 87.17% | 56.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 561.14% | 636.04% | -12.77% | -319.53% | 95.89% |
| Cash from Investing | 432.24% | 580.07% | -8.71% | -370.48% | 94.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.82% | -99.96% | 6.76% | 983.45% | 347.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.59% | -- | -21.54% | 21.54% | -157.30% |
| Cash from Financing | -85.82% | -99.96% | 5.27% | 1,015.51% | 347.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.16% | 108.01% | 80.22% | -95.73% | 179.09% |